MX2022006173A - Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma. - Google Patents
Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma.Info
- Publication number
- MX2022006173A MX2022006173A MX2022006173A MX2022006173A MX2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A MX 2022006173 A MX2022006173 A MX 2022006173A
- Authority
- MX
- Mexico
- Prior art keywords
- gdf15
- fusion protein
- acting
- pharmaceutical composition
- long
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 7
- 102000037865 fusion proteins Human genes 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 9
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 9
- 239000003814 drug Substances 0.000 abstract 4
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000037396 body weight Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003880 negative regulation of appetite Effects 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 239000013636 protein dimer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a una proteína de fusión que incluye una variante de GDF15 que tiene mayor actividad fisiológica y estabilidad in vivo, y una composición farmacéutica que comprende la misma. La variante de GDF15 o proteína de fusión de GDF15 de acción prolongada, de conformidad con la presente invención, es superior a las variantes de GDF15 convencionales en términos de eficacia in vitro, afinidad de unión por los receptores de GDF15 y efecto de pérdida de peso corporal. Por lo tanto, una composición farmacéutica que comprende, como ingrediente activo, la variante GDF15, la proteína de fusión GDF15 de acción prolongada, o un dímero de la proteína de fusión, de la presente invención, provoca la supresión del apetito y, por lo tanto, puede usarse eficazmente como un agente terapéutico para enfermedades metabólicas u obesidad. Además, la composición farmacéutica, que comprende, como ingrediente activo, la variante GDF15, la proteína de fusión GDF15 de acción prolongada o el dímero de la proteína de fusión, puede usarse en terapia combinada o similar con fármacos químicos y otros agentes terapéuticos para el metabolismo. enfermedades, y puede usarse eficazmente en terapia de combinación con agentes terapéuticos convencionales para enfermedades metabólicas u obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190153680 | 2019-11-26 | ||
| PCT/KR2020/016842 WO2021107603A2 (en) | 2019-11-26 | 2020-11-25 | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006173A true MX2022006173A (es) | 2022-06-14 |
Family
ID=76130664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006173A MX2022006173A (es) | 2019-11-26 | 2020-11-25 | Proteinas de fusion gdf15 de accion prolongada y composicion farmaceutica que comprende la misma. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230002460A1 (es) |
| EP (1) | EP4065597A4 (es) |
| JP (1) | JP2023503472A (es) |
| KR (1) | KR20210065057A (es) |
| CN (1) | CN114729020A (es) |
| AU (1) | AU2020394255A1 (es) |
| BR (1) | BR112022010227A2 (es) |
| CA (1) | CA3161302A1 (es) |
| MX (1) | MX2022006173A (es) |
| WO (1) | WO2021107603A2 (es) |
| ZA (1) | ZA202204624B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022333099A1 (en) * | 2021-08-24 | 2024-02-08 | Sunshine Lake Pharma Co., Ltd. | Gdf15 fusion proteins and uses thereof |
| KR20240087545A (ko) * | 2022-11-18 | 2024-06-19 | 주식회사유한양행 | 이중 작용 단백질 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2441466E (pt) | 2004-04-13 | 2014-09-09 | St Vincents Hosp Sydney | Agente de inibição de mic-1 |
| BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
| US9161966B2 (en) * | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| AU2014296107B2 (en) * | 2013-07-31 | 2018-07-26 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| CR20170027A (es) * | 2014-07-30 | 2017-05-09 | Ngm Biopharmaceuticals Inc | Composiciones y métodos de uso para tratar trastornos metabólicos |
| WO2016069925A1 (en) * | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| TWI703161B (zh) * | 2014-10-31 | 2020-09-01 | 美商Ｎｇｍ生物製藥公司 | 用於治療代謝病症之組合物及方法 |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| KR101727506B1 (ko) * | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
-
2020
- 2020-11-25 AU AU2020394255A patent/AU2020394255A1/en active Pending
- 2020-11-25 BR BR112022010227A patent/BR112022010227A2/pt unknown
- 2020-11-25 US US17/779,932 patent/US20230002460A1/en active Pending
- 2020-11-25 CN CN202080081137.8A patent/CN114729020A/zh active Pending
- 2020-11-25 JP JP2022530716A patent/JP2023503472A/ja active Pending
- 2020-11-25 KR KR1020200160013A patent/KR20210065057A/ko unknown
- 2020-11-25 MX MX2022006173A patent/MX2022006173A/es unknown
- 2020-11-25 WO PCT/KR2020/016842 patent/WO2021107603A2/en unknown
- 2020-11-25 EP EP20892374.8A patent/EP4065597A4/en active Pending
- 2020-11-25 CA CA3161302A patent/CA3161302A1/en active Pending
-
2022
- 2022-04-25 ZA ZA2022/04624A patent/ZA202204624B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021107603A2 (en) | 2021-06-03 |
| ZA202204624B (en) | 2023-11-29 |
| US20230002460A1 (en) | 2023-01-05 |
| KR20210065057A (ko) | 2021-06-03 |
| CA3161302A1 (en) | 2021-06-03 |
| WO2021107603A3 (en) | 2021-07-15 |
| AU2020394255A1 (en) | 2022-06-09 |
| CN114729020A (zh) | 2022-07-08 |
| JP2023503472A (ja) | 2023-01-30 |
| EP4065597A2 (en) | 2022-10-05 |
| EP4065597A4 (en) | 2024-01-24 |
| BR112022010227A2 (pt) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204624B (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| WO2007049098A3 (en) | Therapeutic formulations for the treatment of beta-amyloid related diseases | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| UA98462C2 (ru) | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig | |
| WO2006088945A3 (en) | Granulysin peptides and methods of use thereof | |
| IL194500A (en) | A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above | |
| DE60119976D1 (en) | Thixotropes nasenspray | |
| WO2008157369A3 (en) | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus | |
| DE60043886D1 (de) | Formulierungen mit povidon-iod zur behandlung von wunden | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| WO2011014009A3 (ko) | 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 | |
| PL1699468T3 (pl) | Środek farmaceutyczny zawierający kompleks cynk-hialuronian do leczenia stwardnienia rozsianego | |
| TW200621231A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator | |
| WO2003006002A8 (en) | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases | |
| MX2021003030A (es) | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. | |
| MXPA03006266A (es) | Uso de l-carnitina como agente estabilizador de proteinas. | |
| BR0009327A (pt) | Composição farmacêutica para a terapia de sintomas do trato urinário inferior |